The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies
Open accessAbstract
Purpose: ABI-007 is a novel solvent-free, albumin-bound, 130-nm particle formulation of paclitaxel designed to avoid solvent-related toxicities and to deliver paclitaxel to tumors via molecular pathways involving an endothelial cell-surface albumin receptor (gp60) and an albumin-binding protein expressed by tumor cells and secreted into the tumor interstitium (secreted protein acid rich in cysteine). This study determined the maximum-tolerated dose (MTD) of ABI-007 monotherapy administered weekly (three weekly doses, repeated every 4 weeks) and assessed the pharmacokinetics of paclitaxel administered as ABI-007. Patients and Methods: Patients with advanced nonhematologic malignancies received ABI-007 without premedication at dose levels from 80 to 200 mg/m 2 as a 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest (one cycle). Results: Thirty-nine patients were treated with an average of five cycles of ABI-007; 33% of patients received ≥ six cycles of treatment. MTDs for heavily and lightly pretreated patients were 100 and 150 mg/m 2, respectively; and the dose-limiting toxicities were grade 4 neutropenia and grade 3 peripheral neuropathy, respectively. Maximum paclitaxel concentration and area under the curve increased linearly with dose. Dose-dependent changes in plasma clearance did not occur. Partial responses were observed in five patients with breast, lung, and ovarian cancers, all of whom had previously been treated with paclitaxel containing polyoxyethylated castor oil in the formulation. Conclusion: This study demonstrated that weekly ABI-007 can be administered at doses exceeding those typically used for paclitaxel containing polyoxyethylated castor oil. Pharmacokinetics were linear over the dose range studied. Antitumor responses occurred in patients previously treated with paclitaxel containing polyoxyethylated castor oil.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Self-citationRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Self-citationTaxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Self-citationPharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 504
Self-citationTiruppathi, C., Song, W., Bergenfeldt, M., Sass, P., & Malik, A. B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25968 · Cited by 391
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Crown, J., & O'Leary, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02074-2 · Cited by 352
Caveolin regulation of endothelial function
Minshall, R. D., Sessa, W. C., Stan, R. V., Anderson, R. G. W., & Malik, A. B. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00242.2003 · Cited by 302
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer
John, T. A., Vogel, S. M., Tiruppathi, C., Malik, A. B., & Minshall, R. D. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00152.2002 · Cited by 269
Ibrahim, N. K., Samuels, B., Page, R., Doval, D., Patel, K. M., Rao, S. C., Nair, M. K., Bhar, P., Desai, N., & Hortobagyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267
Self-citationMulticenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
Perez, E. A., Vogel, C. L., Irwin, D. H., Kirshner, J. J., & Patel, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4216 · Cited by 250
Distribution of SPARC in normal and neoplastic human tissue.
Porter, P. L., Sage, E. H., Lane, T. F., Funk, S. E., & Gown, A. M. (1995) · Journal of Histochemistry & Cytochemistry · doi:10.1177/43.8.7622842 · Cited by 209
Differential expression of osteonectin/SPARC during human prostate cancer progression.
Thomas, R., True, L. D., Bassuk, J. A., Lange, P. H., & Vessella, R. L. (2000) · PubMed · Cited by 196
Ledda, F., Bravo, A., Adris, S., Bover, L. C., Mordoh, J., & Podhajcer, O. L. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12334263 · Cited by 167
Tiruppathì, C., Finnegan, A., & Malik, A. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.250 · Cited by 146
Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas
Massi, D., Franchi, A., Borgognoni, L., Reali, U. M., & Santucci, M. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90014-x · Cited by 144
Kloover, J. S., den Bakker, M. A., Gelderblom, H. A. J., & van Meerbeeck, J. P. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601303 · Cited by 141
Physician's cancer chemotherapy drug manual 2008
Chu, E., Ma, V., & Devita (2003) · Cited by 134
SPARC: a potential diagnostic marker of invasive meningiomas.
Rempel, S. A., Ge, S., & Gutiérrez, J. A. (1999) · PubMed · Cited by 134
Rempel, S. A., Golembieski, W., Ge, S., et al. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199812000-00002 · Cited by 128
ANALYSIS OF THE GENE EXPRESSION OF SPARC AND ITS PROGNOSTIC VALUE FOR BLADDER CANCER
Yamanaka, M., Kanda, K., Li, N.-C., Fukumori, T., Oka, N., Kanayama, H., & Kagawa, S. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65623-6 · Cited by 103
Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium
Schnitzer, J. E., & Oh, P. (1992) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1992.263.6.h1872 · Cited by 102
Yamashita, K., Upadhay, S., Mimori, K., Inoue, H., & Mori, M. (2003) · Cancer · doi:10.1002/cncr.11368 · Cited by 80
Activation of SPARC Expression in Reactive Stroma Associated with Human Epithelial Ovarian Cancer
Brown, T. J., Shaw, P. A., Karp, X., et al. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5552 · Cited by 75
Schilling, U., Friedrich, E. A., Sinn, H., Schrenk, H. H., Clorius, J. H., & Maier‐Borst, W. (1992) · International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology · doi:10.1016/0883-2897(92)90103-6 · Cited by 47
Tolcher, A. W., Eckhardt, S. G., Kuhn, J. G., Hammond, L. A., Weiss, G. R., Rizzo, J. D., Aylesworth, C. A., Hidalgo, M. M., Patnaik, A., Schwartz, G. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2937 · Cited by 36
Reversible ligand binding to human serum albumin. Theoretical and clinical aspects.
Vorum, H. (1999) · PubMed · Cited by 33
Cited by
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Ernsting, M. J., Murakami, M., Roy, A., & Li, S.-D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.013 · Cited by 1,012
Nanoparticles in cellular drug delivery
Faraji, A. H., & Wipf, P. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.043 · Cited by 903
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Self-citation
Metadata
- Authors
- Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., & Von Hoff, D. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-01
- Volume
- 23
- Issue
- 31
- Pages
- 7785-7793
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2078775260
- Cited by
- 286
- References
- 35
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.